Overactive Bladder (OAB)

Canadian Urological Association 

• Overview of management of overactive bladder including diagnostics and treatment recommendations  

1. The following medications may contribute to overactive bladder EXCEPT? 

a) SGLT2 inhibitors 

b) Diuretics 

c) Cholinesterase inhibitors  

d) Alpha blockers 

2. Which of the following is NOT a sign/symptom of overactive bladder? 

a) Dysuria 

b) Urgency 

c) Frequency 

d) Nocturia 

3. True or false: selective anti-muscarinic agents have fewer adverse effects than non-selective 

a) True

b) False

4. What is the recommended treatment trial period before determining if OAB therapy is effective? 

a) 1-2 weeks at target dose 

b) 2-4 weeks at target dose 

c) 4-8 weeks at target dose 

d) 8-12 weeks at target dose 

5. Which of the following products have fewer rates of adverse events? 

a) Oxybutynin SR

b) Oxybutynin patch

c) Mirabegron

d) All of the above